Discover
GHRS
GH Research PLC
28.26
2 x 20.99
2 x 36.60
bid
ask
-
0.46
1.60%
2 @ 07:30 PM
28.26 +0.00 (0.00%)
| Ytd | 122.52% | |
| 1y | 113.77% |
28.00
day range
29.15
12.48
52 week range
30.64
| Open | 28.87 | Prev Close | 28.72 | Low | 28.00 | High | 29.15 | Mkt Cap | 1.94B |
| Vol | 132.83K | Avg Vol | 277.17K | EPS | -0.99 | P/E | N/A | Forward P/E | -15.28 |
| Beta | 1.28 | Short Ratio | 10.32 | Inst. Own | 71.38% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-05 | 50-d Avg | 28.27 | 200-d Avg | 20.36 | 1yr Est | 42.89 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-11-05 | 2026-09 | -0.27 | N/A | N/A | N/A |
| 2026-08-06 | 2026-06 | -0.29 | -0.23 | 0.06 | 19.58% |
| 2026-05-14 | 2026-03 | -0.27 | -0.31 | -0.04 | -14.81% |
| 2026-03-05 | 2025-12 | -0.29 | -0.23 | 0.06 | 20.69% |
| 2025-11-06 | 2025-09 | -0.23 | -0.23 | N/A | N/A |
| 2025-08-07 | 2025-06 | -0.22 | -0.15 | 0.07 | 31.82% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-08-07 | Guggenheim | Upgrade | Buy | Buy |
| 2026-08-07 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
| 2026-08-06 | Needham | Upgrade | Buy | Buy |
| 2026-07-27 | Wells Fargo | Upgrade | Overweight | |
| 2026-05-19 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-05-15 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
Profile
GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression. It also develops GH002, an intravenous mebufotenin product candidate, which is in phase 1 clinical pharmacology trial in healthy volunteers focusing on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | Lynx1 Capital Management Lp | 13.26M | 374.82M | 19.33% |
| 2026-06-29 | BVF Inc. | 8.65M | 244.45M | 12.61% |
| 2026-06-29 | RA Capital Management, L.P. | 7.64M | 215.82M | 11.13% |
| 2026-06-29 | FMR, LLC | 5.98M | 168.91M | 8.71% |
| 2026-06-29 | RTW Investments LP | 5.93M | 167.69M | 8.65% |
| 2026-06-29 | Deep Track Capital, Lp | 3.33M | 94.20M | 4.86% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-07-30 | Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 1.90M | 53.57M | 2.76% |
| 2026-07-30 | Fidelity Mt. Vernon Street Trust-Fidelity Growth Company K6 Fund | 616.54K | 17.42M | 0.90% |
| 2026-07-30 | Fidelity Mt. Vernon Street Trust-Fidelity Series Growth Company Fund | 476.70K | 13.47M | 0.69% |
| 2026-07-30 | iShares Trust-iShares Biotechnology ETF | 356.39K | 10.07M | 0.52% |
| 2026-07-30 | Fidelity Select Portfolios-Select Biotechnology Portfolio | 173.40K | 4.90M | 0.25% |
| 2026-08-30 | AdvisorShares Trust-AdvisorShares Psychedelics ETF | 90.07K | 2.55M | 0.13% |